Expiry of Share Options

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Expiry of share options

Brighton, United Kingdom - 5 September 2022 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that 602,000 options ("Options") over ordinary shares of 1 pence in the Company have expired under the Company's EMI Scheme 2000, of which 406,500 Options relate to Dr William Love, Chief Scientific Officer.

Following the expiry of the Options, a total of 8,875,230 options remain outstanding in the Company with Dr Love holding options over 916,236 ordinary shares representing 1.25% of ordinary shares in the Company.

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

[email protected]

Optimum Strategic Communications

Mary Clark / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891

[email protected] 

finnCap Ltd (Nominated Adviser and Joint Broker)

Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

MC Services AG

Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

Stern IR

Lilian Stern / Janhavi Mohite

+1-212-362-1200

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV™, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com